Do analysts recommend ARTL or TRAW?

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 86.57%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than Artelo Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has better earnings & valuation, ARTL or TRAW?

Traws Pharma is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artelo Biosciences N/A N/A -$12.88M -$151.22 N/A Traws Pharma N/A N/A $9.17M -$1.74 N/A

Is ARTL or TRAW more profitable?

Artelo Biosciences' return on equity of -518.27% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -518.27% -194.29% Traws Pharma N/A -23,868.92% -165.52%

Does the media prefer ARTL or TRAW?

In the previous week, Artelo Biosciences and Artelo Biosciences both had 1 articles in the media. Artelo Biosciences' average media sentiment score of 1.32 beat Traws Pharma's score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artelo Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer OBSV or ARTL?

Given ObsEva's higher possible upside, equities research analysts clearly believe ObsEva is more favorable than Artelo Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Artelo Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation & earnings, OBSV or ARTL?

Artelo Biosciences is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A Artelo Biosciences N/A N/A -$12.88M -$151.22 N/A

Is OBSV or ARTL more profitable?

ObsEva's return on equity of -416.36% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% Artelo Biosciences N/A -518.27% -194.29%

Do analysts prefer ARTL or CURX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ARTL or CURX?

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artelo Biosciences N/A N/A -$12.88M -$151.22 N/A Curanex Pharmaceuticals N/A N/A -$4.22M -$7.80 N/A

Is ARTL or CURX more profitable?

Curanex Pharmaceuticals' return on equity of -82.07% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -518.27% -194.29% Curanex Pharmaceuticals N/A -82.07% -79.65%

Do analysts prefer ARTL or ENSC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ARTL or ENSC?

In the previous week, Artelo Biosciences and Artelo Biosciences both had 1 articles in the media. Artelo Biosciences' average media sentiment score of 1.32 beat Ensysce Biosciences' score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artelo Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ensysce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CNSP or ARTL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Artelo Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings & valuation, CNSP or ARTL?

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CNS Pharmaceuticals N/A N/A -$15.85M -$23.59 N/A Artelo Biosciences N/A N/A -$12.88M -$151.22 N/A

Is CNSP or ARTL more profitable?

CNS Pharmaceuticals' return on equity of -204.25% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -204.25% -141.87% Artelo Biosciences N/A -518.27% -194.29%

Artelo Biosciences (ARTL) Competitors

$3.51 -0.17 (-4.62%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$3.69 +0.18 (+5.10%)

As of 07:13 AM Eastern

Compare

ARTL vs. TRAW, OBSV, CURX, ENSC, and CNSP

Should you buy Artelo Biosciences stock or one of its competitors? Artelo Biosciences's main competitors and comparable companies include Traws Pharma (TRAW), ObsEva (OBSV), Curanex Pharmaceuticals (CURX), Ensysce Biosciences (ENSC), and CNS Pharmaceuticals (CNSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Artelo Biosciences compare to Traws Pharma?

Artelo Biosciences (NASDAQ:ARTL) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Artelo Biosciences' return on equity of -518.27% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-518.27%	-194.29%
Traws Pharma	N/A	-23,868.92%	-165.52%

Traws Pharma is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$151.22	N/A
Traws Pharma	N/A	N/A	$9.17M	-$1.74	N/A

Artelo Biosciences has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 7.9% of Traws Pharma shares are held by institutional investors. 3.2% of Artelo Biosciences shares are held by insiders. Comparatively, 7.6% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Artelo Biosciences and Artelo Biosciences both had 1 articles in the media. Artelo Biosciences' average media sentiment score of 1.32 beat Traws Pharma's score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artelo Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 86.57%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than Artelo Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Traws Pharma beats Artelo Biosciences on 8 of the 11 factors compared between the two stocks.

How does Artelo Biosciences compare to ObsEva?

ObsEva (NASDAQ:OBSV) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

ObsEva's return on equity of -416.36% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Artelo Biosciences	N/A	-518.27%	-194.29%

Artelo Biosciences is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$151.22	N/A

In the previous week, Artelo Biosciences had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for Artelo Biosciences and 0 mentions for ObsEva. Artelo Biosciences' average media sentiment score of 1.32 beat ObsEva's score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
ObsEva	Neutral
Artelo Biosciences	Positive

17.5% of ObsEva shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 14.4% of ObsEva shares are held by insiders. Comparatively, 3.2% of Artelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

Given ObsEva's higher possible upside, equities research analysts clearly believe ObsEva is more favorable than Artelo Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Artelo Biosciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

ObsEva beats Artelo Biosciences on 8 of the 12 factors compared between the two stocks.

How does Artelo Biosciences compare to Curanex Pharmaceuticals?

Artelo Biosciences (NASDAQ:ARTL) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$151.22	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A

In the previous week, Artelo Biosciences had 1 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 1 mentions for Artelo Biosciences and 0 mentions for Curanex Pharmaceuticals. Artelo Biosciences' average media sentiment score of 1.32 beat Curanex Pharmaceuticals' score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Artelo Biosciences	Positive
Curanex Pharmaceuticals	Neutral

0.9% of Artelo Biosciences shares are held by institutional investors. 3.2% of Artelo Biosciences shares are held by company insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Artelo Biosciences has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, Curanex Pharmaceuticals has a beta of -2.88, indicating that its share price is 388% less volatile than the broader market.

Curanex Pharmaceuticals' return on equity of -82.07% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-518.27%	-194.29%
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%

Summary

Artelo Biosciences beats Curanex Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Artelo Biosciences compare to Ensysce Biosciences?

Artelo Biosciences (NASDAQ:ARTL) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

Ensysce Biosciences has higher revenue and earnings than Artelo Biosciences. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$151.22	N/A
Ensysce Biosciences	$5.07M	1.61	-$10.18M	-$2.76	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Artelo Biosciences has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. Artelo Biosciences' return on equity of -518.27% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-518.27%	-194.29%
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%

Artelo Biosciences has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 3.2% of Artelo Biosciences shares are held by insiders. Comparatively, 2.8% of Ensysce Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Artelo Biosciences and Artelo Biosciences both had 1 articles in the media. Artelo Biosciences' average media sentiment score of 1.32 beat Ensysce Biosciences' score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artelo Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ensysce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Artelo Biosciences beats Ensysce Biosciences on 7 of the 12 factors compared between the two stocks.

How does Artelo Biosciences compare to CNS Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$151.22	N/A

CNS Pharmaceuticals' return on equity of -204.25% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-204.25%	-141.87%
Artelo Biosciences	N/A	-518.27%	-194.29%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Artelo Biosciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 1.8% of CNS Pharmaceuticals shares are owned by insiders. Comparatively, 3.2% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Artelo Biosciences had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 1 mentions for Artelo Biosciences and 0 mentions for CNS Pharmaceuticals. Artelo Biosciences' average media sentiment score of 1.32 beat CNS Pharmaceuticals' score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
CNS Pharmaceuticals	Neutral
Artelo Biosciences	Positive

CNS Pharmaceuticals has a beta of 3.1, meaning that its share price is 210% more volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market.

Summary

Artelo Biosciences beats CNS Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Artelo Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARTL vs. The Competition

Export

Metric	Artelo Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.02M	$12.24B	$7.14B	$13.26B
Dividend Yield	N/A	2.65%	2.54%	17.37%
P/E Ratio	-0.02	799.72	274.34	26.20
Price / Sales	N/A	790.22	577.41	78.74
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	-0.21	10.67	11.20	6.40
Net Income	-$12.88M	$2.83B	$3.49B	$381.07M
7 Day Performance	-13.76%	-2.04%	-1.37%	-0.30%
1 Month Performance	-41.89%	-6.58%	-6.02%	-4.53%
1 Year Performance	-97.10%	-4.72%	7.24%	1.62%

Artelo Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
ARTL Artelo Biosciences	1.1475 of 5 stars	$3.51 -4.6%	N/A	-97.2%	$2.02M	N/A	N/A	7
TRAW Traws Pharma	1.5209 of 5 stars	$0.63 +8.1%	$1.00 +59.7%	-76.2%	$8.90M	N/A	N/A	7
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
CURX Curanex Pharmaceuticals	0.3817 of 5 stars	$4.97 -1.2%	N/A	-68.2%	$7.90M	N/A	N/A	6
ENSC Ensysce Biosciences	1.0899 of 5 stars	$0.42 +4.0%	N/A	-83.5%	$7.80M	$5.07M	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARTL) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artelo Biosciences (ARTL) Competitors

ARTL vs. TRAW, OBSV, CURX, ENSC, and CNSP

How does Artelo Biosciences compare to Traws Pharma?

Summary

How does Artelo Biosciences compare to ObsEva?

Summary

How does Artelo Biosciences compare to Curanex Pharmaceuticals?

Summary

How does Artelo Biosciences compare to Ensysce Biosciences?

Summary

How does Artelo Biosciences compare to CNS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artelo Biosciences (ARTL) Competitors

ARTL vs. TRAW, OBSV, CURX, ENSC, and CNSP

How does Artelo Biosciences compare to Traws Pharma?

Is ARTL or TRAW more profitable?

Which has better earnings & valuation, ARTL or TRAW?

Which has more volatility & risk, ARTL or TRAW?

Do insiders & institutionals believe in ARTL or TRAW?

Does the media prefer ARTL or TRAW?

Do analysts recommend ARTL or TRAW?

Summary

How does Artelo Biosciences compare to ObsEva?

Is OBSV or ARTL more profitable?

Which has higher valuation & earnings, OBSV or ARTL?

Does the media refer more to OBSV or ARTL?

Do institutionals and insiders have more ownership in OBSV or ARTL?

Which has more volatility & risk, OBSV or ARTL?

Do analysts prefer OBSV or ARTL?

Summary

How does Artelo Biosciences compare to Curanex Pharmaceuticals?

Do analysts prefer ARTL or CURX?

Which has stronger valuation and earnings, ARTL or CURX?

Does the media refer more to ARTL or CURX?

Do insiders & institutionals have more ownership in ARTL or CURX?

Which has more risk & volatility, ARTL or CURX?

Is ARTL or CURX more profitable?

Summary

How does Artelo Biosciences compare to Ensysce Biosciences?

Which has better earnings & valuation, ARTL or ENSC?

Do analysts prefer ARTL or ENSC?

Is ARTL or ENSC more profitable?

Which has more volatility & risk, ARTL or ENSC?

Do institutionals and insiders have more ownership in ARTL or ENSC?

Does the media refer more to ARTL or ENSC?

Summary

How does Artelo Biosciences compare to CNS Pharmaceuticals?

Which has better earnings & valuation, CNSP or ARTL?

Is CNSP or ARTL more profitable?

Do analysts prefer CNSP or ARTL?

Do institutionals & insiders believe in CNSP or ARTL?

Does the media favor CNSP or ARTL?

Which has more volatility and risk, CNSP or ARTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools